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Abstract: Tumors often show intra-tumor heterogeneity because of genotypic differences between
all the cells that compose it and that derive from it. Recent studies have shown significant aspects
of neuroblastoma heterogeneity that may affect the diagnostic-therapeutic strategy. Therefore, we
developed a laboratory protocol, based on the combination of the advanced dielectrophoresis-based
array technology and next-generation sequencing to identify and sort single cells individually and
carry out their copy number variants analysis. The aim was to evaluate the cellular heterogeneity,
avoiding overestimation or underestimation errors, due to a bulk analysis of the sample. We tested the
above-mentioned protocol on two neuroblastoma cell lines, SK-N-BE(2)-C and IMR-32. The presence
of several gain or loss chromosomal regions, in both cell lines, shows a high heterogeneity of the
copy number variants status of the single tumor cells, even if they belong to an immortalized cell line.
This finding confirms that each cell can potentially accumulate different alterations that can modulate
its behavior. The laboratory protocol proposed herein provides a tool able to identify prevalent
behaviors, and at the same time highlights the presence of particular clusters that deviate from them.
Finally, it could be applicable to many other types of cancer.
Keywords: intra-tumor heterogeneity; single cell isolation; whole genome amplification;
next-generation sequencing; copy number variations; chromosomal pattern
1. Introduction
It is widely accepted that cancer is a highly heterogeneous disease and that subpopulations of
cells, within a single tumor, can exhibit distinct genomic profiles. Indeed, the ensemble behaviors of a
cellular population may not represent the behavior of any individual cell [1]. Recent technological
advances made it possible to analyze nucleic acids and proteins from different areas of a single tumor,
as well as within a heterogeneous tumor sample, reaching single-cell resolution. In this way, it is
possible to avoid the averaging of bulk analysis and to capture the heterogeneity of cells [2].
In the case of Neuroblastoma (NB), where high cellular heterogeneity is a hallmark, the wide
range of clinical presentations and the uneven response to treatment seem to be due to cellular
heterogeneity [3]. NB heterogeneity is related to tumor differentiation and histology: it derives from
multipotent Neural Crest Cells (NCCs), forms during embryonic development, and mainly involves
the sympathetic nervous system (abdomen, especially the adrenal gland) [4,5].
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The occurrence of NB is at early infancy and childhood, almost all NB cases being diagnosed at the
age of 10 (98%). NB survival rate depends on the success of the treatment and the rate of diagnosis [6].
Nearly 50% of patients have a localized tumor (primary site) with an average survival rate of about five
years, while in the other 50% of patients, it occurs in an advanced, final stage [7]. Generally, patients
aged more than 1.5 years at diagnosis have much worse outcomes than infants, and the presence of the
metastatic stage denotes a poor prognosis [8]. Genetics plays a crucial role in the NB tumorigenesis;
in fact, two key factors to identify the progression and prognosis of the tumor are the detection of
structural Copy Number Variations (CNVs) and the amplification of the MYCN gene, able to identify
those tumors with poor prognosis and rapid progression, independently of age and clinical stage [7–9].
However, MYCN amplification can only be seen in about 25% of NB patients; thus, other contributing
factors that are still unknown or not tested have to be implicated in the other cases [10].
Sometimes, genetic variations, which affect only a small number of cells, can be undetectable,
especially if the molecular analysis is performed on a larger mixed pool of normal and variant tumor
cells [11]. As a consequence, the signal of the tumor cells that are driving the progression of the tumor
could be hidden. The characterization of single cells would allow highlighting the presence of possible
subpopulations or providing further information on the genetic identity of the cells.
Therefore, the purpose of this study was to develop a laboratory protocol that allows the
evaluation of the cellular heterogeneity, avoiding incurring over- or under-estimation errors. We used
a combination between the advanced DEPArray™ technology and Next-Generation Sequencing (NGS)
to identify, manipulate, and sort single cells individually and then to carry out their CNV analysis.
The presence of chromosomal alterations, some common to all cells and others specific to a few cells,
first allowed identifying the cellular subpopulations and, subsequently, checking for genes that were
located in those regions.
2. Results
The combined use of the DEPArrayTM technology platform with NGS allowed analyzing 33 single
cells isolated from two neuroblastoma cell lines, namely SK-N-BE (2)-C and IMR-32.
Of the 24 cells isolated from the IMR-32 plate, 19 were considered suitable for the analysis of the
chromosomal pattern, which allowed highlighting in all 19 IMR-32 single cells the presence of a total
gain of chromosome 6, 2 partial gains, 1 in the chromosomal region between 1p32.3 and 1q44 (194 Mb)
and the other in the chromosomal region between 17q21.31 and 17q25.3 (39 Mb), and a partial loss
of the chromosomal region between 16q22.2 and 16q24.3 (18 Mb). Moreover, all cells showed a gain
in chromosome 15, although it was total only in 15/19 cells (Figure 1) and partial (15q15.3–15q26.3)
in the other 4 (Figure 2). Notable identifications were the total loss of chromosomes X (2/19) and
13 (1/19) and a partial loss of chromosome 11, i.e., 11p15.2–11p21 (42 Mb), 11q14.1–11q23.2 (32 Mb),
ad 11q23.2–11q26.3 (21 Mb) in 1 cell.
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Figure 2. CNV chart related to a single cell from I R-32 showing, from left to right, partial gain of
chromosome 1, total gain of chromosome 6, partial gain of chromosome 15, a partial loss of chromosome
16, a partial gain of chromosome 17, and the total loss of the X chromosome.
All 14 isolated single cells from SK-N-BE (2)-C presented a partial gain of chromosomes
7 (7q32.1–q36.3 of 27 Mb) and 11 (11q13.3–11q25 of 65 Mb), a total loss of X chromosome, and a partial
loss of chromosomes 3 (3p26.3–3p14.2 of 61 Mb), 13 (13q12.11–13q31 of 66 Mb), 17 (17p13.3–17q11.2 of
30 Mb), 19 (19q12–19q13.43 of 28 Mb) and 21 (21q22.2–q22.3 of 6 Mb).
In 8/14 cells, a partial gain of chromosome 1 was found (1p32.3–1q44 of 151 Mb) (Figure 3);
moreover, 5/14 cells showed a partial l ss in that chromosome (1p32.2– p21.3 of 44 Mb) (Figure 4);
6/14 cells had part l i of chrom somal region between 2p25 3 and 2p21 (44 Mb); and just 1 cell
showed a peculiar gain of chromosome 9, i.e., 9p24.3–9p23 (13 Mb).
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Int. J. ol. Sci. 2018, 19, x FOR PEER REVIE   3 of 14 
 
Figure 1. C V chart related to a single cell fro  I R-32 sho ing, fro  left to right, partial gain of 
chro oso e 1, total gain of chro oso es 6 and 15, a partial loss of chro oso e 16, a partial gain in 
chro oso e 17, and the total loss of the X chro oso e. 
 
Figure 2. C V chart related to a single cell fro  I R-32 sho ing, fro  left to right, partial gain of 
chro oso e 1, total gain of chro oso e 6, partial gain of chro oso e 15, a partial loss of 
chro oso e 16, a partial gain of chro oso e 17, and the total loss of the X chro oso e. 
ll 14 isolated single cells fro  SK- -BE (2)-C presented a partial gain of chro oso es 7 
(7q32.1–q36.3 of 27 b) and 11 (11q13.3– 1q25 of 65 b), a total loss of X chro oso e, and a partial 
loss of chro oso es 3 (3p26.3–3p14.2 of 61 b), 13 (13q12.11–13q31 of 66 b), 17 (17p13.3–17q11.2 
of 30 b), 19 (19q12–19q13.43 of 28 b) and 21 (21q22.2–q22.3 of 6 b). 
In 8/14 cells, a partial gain of chro oso e 1 as found (1p32.3–1q44 of 151 b) (Figure 3); 
oreover, 5/14 cells sho ed a partial loss in that chro oso e (1p32.2–1p21.3 of 44 b) (Figure 4); 
6/14 cells had partial gain of chro oso al region bet een 2p25.3 and 2p21 (44 b); and just 1 cell 
sho ed a peculiar gain of chro oso e 9, i.e., 9p24.3–9p23 (13 b). 
 
Figure 3. C V chart r la ed to a single cell fro  SK- -BE (2)-C sho ing, fro  left to right,  
gain of chro oso e 1, partial loss of chro oso es 3, partial gain of chro oso es 7 and 11, a partial 
loss of chro oso es 13, 17, 19, and 21, and the total loss of the X chro oso e. 
 
Figure 4. C V chart related to a single cell fro  SK- -BE (2)-C sho ing, fro  left to right, partial 
loss of chro oso e 1, partial gain of chro oso e 2, partial loss of chro oso es 3, partial gain of 
chro oso es 7 and 11, a partial loss of chro oso es 13, 17, 19, and 21, and the total loss of the X 
chro oso e. 
Figure 4. CNV chart related to a single cell from S -N-BE (2)-C showing, from left to right, partial
loss of chromosome 1, partial gain of chromosome 2, partial loss of chromosomes 3, partial gain of
chromosomes 7 and 11, a partial loss of chromosomes 13, 17, 19, and 21, and the total loss of the
X chromosome.
Definitely, these results show that, among the 19 single cells isolated from the same IMR-32
cell line, 5 different chromosomal patterns were identified (Figure 5), and among the 14 single cells
isolated from the SK-N-BE (2)-C cell line, 4 different chromosomal patterns were identified (Figure 6),
highlighting the importance of the analysis at the single-cell level.
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3. Discussion
Cancers often exhibit intra-tumor heterogeneity due to genotypic differences between individual
cells present in the tumor itself. Molecular characterization of sin le cells is pivotal for a reliable
ge omic analysis, since it allows av iding the l ss of sensitivity derived from the analysis of samples
in which different cells coexist or that derive from more cell clones.
Th evaluation of NB cell he erogeneity had been pr viously approached; however,
the chromosomal pattern at the singl -cell level had nev r been tested before [3].
The protocol w have d velop d her in, t nks to both the analysis of the CNVs and the definition
of chromosomal patterns, underlines the importance of the analysis at the single-cell level; indeed, for
both SK-N-BE (2)-C and IMR-32, it was able to det ct the presence of different chromosomal patterns
within the same cell line. In addition, starting from the evaluation of chromosomal patterns, we first
checked the presence of possible cell subpopulations (Figures 5 and 6) and then looked for the genes
present in the affected genomic areas by consultation of the gene bank software (Tables 1 and 2).
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Although the relationship between the presence of gain or loss of chromosomal regions and
cancer has not been permanently established, it is certainly evident that the loss of tumor suppressor
genes (chromosomal deletion) and the overexpression of oncogenes (chromosomal duplication) are
consistent with the nature of cancer. For example, the amplified copies of oncogene MYCN located in
the 2p25–p22 region confer resistance to some treatments used for NB therapy. Patients with amplified
MYCN have markedly poorer prognosis than those in which MYCN copy number is not elevated [9].
Table 1. The table shows the gain or loss chromosomal regions identified in the 19 IMR-32 single
cells analyzed and the main genes implicated in the mechanisms of cancer regulation, according to
recent literature.
Gene
Single Cell Chr. Alteration Name Position Features and Implications with Cancer
19/19
1p32-3–1q44
(194 Mb)
JUN 1p32.1 Cell proliferation and transformation
RAPIA 1p13.2 Activator of Raf gene in the MAP kinase pathway
RHOC 1p13.2 Believed to have a similar function as Ras
NRAS 1p31.2 Signal transduction pathways
AKT3 1q43–q44 Cell proliferation, survival, and tumorigenesis
6
FOXQ1 6p25.3 Increased migration and proliferation
SOX4 6p22.3 Increased survival in medulloblastoma
AGER 6p21.32 Promoter of human glioblastoma cell growth and migration
SRSF3 6p21.31 Cell cycle progression control
NCR2 6p21.1 Cell cycle regulation
HACE1 6q16.3 Tumor suppressor
LATS1 6q24-25.1 Overexpression reduces cell proliferation, migration. and invasion
17q21.1–17q25.3
(42 Mb)
SLC4A1 16q22.2 Overexpression leads to tumor progression
NMT1 16q23.1 Upregulated due to gene amplification
FMNL1 16q24.1 Overexpression leads to cell growth
NGFR 16q24.1 Acts as a tumor marker for neural crest cells
16q21–16q24.2
(26 Mb)
ZFHX3 17q21.31 Neuronal differentiation
WWOX 17q21.31 Possible involvement in apoptosis
FXOP1 17q21.31 Cell cycle progression, invasion, and metastasis
WEDC1 17q21.33 Functions like the tumor suppressor gene
15/19 15
PLCB2 15q15.1 Overexpressed in cancer tissues
TYRO3 15q15.1 Highly expressed in certain cancers
4/19
15q15.1–15q26.3
(60 Mb)
RASGRF1 15q25.1 Overexpression in the MAPK cascade in neuronal cells
PCSK6 15q26.3 High expression in breast cancer and prostate cancer
1/19
11p15.2–11p12
(42 Mb);
11q14.1–11q23.2
(32 Mb);
11q23.2–11q25
(21 Mb)
HTATIP2 11p15.1 Suppression of metastasis in various tumors
WT1 11p13 Tumor suppressor
MRE11 11q21 DNA repair mechanism
ATM 11q22.3 DNA repair mechanism
1/19 13 See Table 2
2/19 X
VEGFD Xp22.2 Angiogenesis, lymphangiogenesis, and metastasis
PRDX4 Xp22.11 Facilitates protein folding
ZBTB33 Xq24 Both an activator and repressor of transcription
PASD1 Xq28 Transcription factor
L1CAM Xq28 Axon outgrowth and neuronal migration
VEGFD Xp22.2 Angiogenesis, lymphangiogenesis, and metastasis
Legend
Partial gain
Total gain
Partial loss
Total loss
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Table 2. The table shows the gain or loss chromosomal regions identified in the 14 SK-N-BE (2)-C
single cells analyzed and the main genes implicated in the mechanisms of cancer regulation, according
to recent literature.
Gene
Single Cell Chromosomal Alteration Name Position Features and Implications with Cancer
14/14
7q32.1–7q36.3
(31 Mb)
NRF1 7q32.3 Cell cycle regulation
BRAF 7q34 Belongs to the RAS/RAF/MEK/ERK/MAPK pathway
EPHB6 7q34 Prognostic indicators in neuroblastoma
EZH2 7q36.1 Role in the control of the central nervous system
XRCC2 7q36.1 Involved in homologous recombination
11q13.3–11q25
(65 Mb)
MRE11 11q21 DNA repair mechanism
ATM 11q22.3 DNA repair mechanism
MCAM 11q23.3 Cell adhesion molecules
FLI1 11q24.3 Role in erythropoiesis
TMPRSS4 11q23.3 Role in invasion, metastasis, migration, and adhesion
3p26.3–3p14.2
(61 Mb)
PPARG 3p25.2 Anti-inflammatory role
TGFBR2 3p24.1 Loss of expression is linked with cancer
MLH1 3p22.2 Recruitment of proteins for excision and repair
BAP1 3p21.1 Enhances BRCA1-mediated inhibition
13q12.11–13q31.1
(66 Mb)
LATS2 13q12.11 Overexpression inhibits tumor formation
PDX1 13q12.2 Overexpression is correlated with metastasis
BRCA2 13q13.1 Maintenance of genomic integrity
RB1 13q14.2 Cell cycle regulation and differentiation
KLF5 13q22.1 Cell cycle, cell proliferation, and apoptosis
LATS2 13q12.11 Overexpression inhibits tumor formation
17p13.3–17q11.2
(30 Mb)
FAM57A 17p13.3 Amino acid transport and glutathione metabolism
CRK 17p13.3 Overexpressed in various human cancers
MAP2K4 17p12 Response to cellular stress
NF1 17q11.2 Loss of function leads to neurofibromatosis type 1
KSR1 17q11.2 Might be involved in Ras-mediated oncogenesis
19q12–19q13.43
(28 Mb)
PDCD5 19q13.11 Promotes apoptosis; underexpressed
FXYD3 19q13.12 Downregulated in various cancers
PAF1 19q13.2 Overexpression results in enhanced growth rates
BAX 19q13.33 Proapoptotic function
ATF5 19q13.33 Proliferation and differentiation of neural cells
21q22.2–21q22.3
(6 Mb)
ERG 21q22.2 Regulator of mitogenic signal transduction pathways
ETS2 21q22.3 Positive or negative regulator of gene expression
TMPRSS2 21q22.3 Involved in prostate cancer
CSTB 21q22.3 Related to a favorable prognosis for cancer patients
PTTG1IP 21q22.3 Overexpressed in thyroid tumors
X See Table 1
8/14
1p21.3–1q44
(151 Mb)
ABL2 1q25.2 Involved in acute non-lymphocytic leukemia
TP53BP2 1q43–44 Apoptosis, cell cycle, tumor suppression, and cell polarity
5/14
1p32.2–1p21.3
(44 Mb)
JUN 1p32.1 Cell proliferation and transformation
JAK1 1p31.3 Signaling by the majority of cytokines
GADD45A 1p31.3 Maintenance of genome integrity
NRAS 1p31.2 Signal transduction pathways
6/14
2p25.3–2p21
(44 Mb)
SOX11 2p25.2 Development in the nervous system of the human fetus
ID2 2p25.1 Phenotypic transition of neuroblastoma tumor cells
N-Myc 2p24.3 Expressed in several tumors
ALK 2p23.2 Development and maintenance of the nervous system
EPCAM 2p21 Oncogenic signaling molecule
1/14
9p24.3–9p23
(13 Mb)
JAK2 9p24.1 Associated with cytokine receptors
RLN2 9p24.1 Induced by a variety of factors in different tissues
PTPRD 9p24.1 Tumor suppressor gene in neuroblastoma
TYRP1 9p23 Correlated with distant metastasis-free survival
Legend
Partial gain
Total gain
Partial loss
Total loss
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Although the aim of this work is not to draw conclusions about the impact that the combination
of more or less expressed genes may have on tumor progression, in Tables 1 and 2, we report the
main genes present in the affected genomic regions and the corresponding literature highlighting their
implications for cancer.
In particular, concerning the IMR-32 cell line, the main subpopulation is characterized by the
duplication of chromosomes 6 and 15, partial gain of chromosomes 1 and 17, and partial loss of
chromosome 16 (Table 1). The presence of a supernumerary 6 chromosome in all the IMR-32 single
cells analyzed can be related to the Single-Nucleotide Polymorphisms (SNPs), FLJ22536 and FLJ44180,
in position 6p22, previously described to be associated with the sporadic form of NB [12]. In this same
position, three SNPs, namely CASC15, CASC15-S, and CASC14, were identified by Genome-Wide
Association Study (GWAS) and associated with metastatic disease, amplification of MYCN oncogene,
and more advanced disease [13–15].
The analysis of the other gain regions in the IMR-32 single cells revealed the presence of many
genes related to the development and progression of the cancer. For example, in the 1p32.3–1q44 region,
notable genes are: JUN and AKT3, which play a major role in cell proliferation and transformation;
RAPIA and RHOC, implicated in the RAS pathway; and N-RAS, involved in the signal transduction
pathway [16–20]. As reported in Table 1, in the regions 17q21.31–17q25.3 and 15q15.1–15q26.3, there
are some genes that have been previously implicated in human cancer, even if until now not in NB.
It is noteworthy that every single cell had a common deletion in the long arm of chromosome
16 (16q22.2–16q24.3), where some notable genes are located, i.e., ZFHX3 (involved in neuronal
differentiation), WWOX (involved in apoptosis and downregulated or highly undetected in breast
cancer cell lines), and FXOP1 and WEDC (both seem to play a role in prostate cancer) [21–24].
In just 1 single IMR-32 cell, we found a deletion on chromosome 11 (11p15.2–11p12;
11q14.1–11q23.2; 11q23.2–11q25), which appears to be present in nearly 20–45% of NB patients. This
alteration has been related to the development of a more aggressive neuroblastoma with a decreased
survival rate [25,26]. By analyzing the genes present in the deleted region, a correlation can be found
between the deletion and disease progression. Indeed, in this region, there are 4 genes that deserve to be
reported: 2 of these are known to be tumor suppressors, HTATIP2 (involved in metastasis suppression
in several tumors) and WT1 (whose deletion is associated with nephroblastoma in children); the other 2,
MRE11 and ATM, have been reported to be involved in DNA repair mechanisms; thus, their loss of
function may lead to defective DNA repair, which in turn, leads to cancer [27–29].
Finally, 2 single cells showed a loss of chromosome X, which is peculiar in this study. Among
the genes located in the X chromosome that appear to be implicated in cancer (i.e., VEGFD, PRDX4,
ZBTB33, PASD1), the 1 that mainly could be correlated with NB is L1CAM, since it plays a role in axon
outgrowth and fasciculation, neuronal migration, and survival, synaptic plasticity, and regeneration
after trauma [30].
The single cells isolated from the SK-N-BE (2)-C cell line share most of the genetic aberrations
identified (Figure 6). The analysis of the chromosomal patterns allowed identifying a main
subpopulation (8/14) characterized by the presence of the partial gain of chromosomes 7 and 11,
the partial loss in chromosomes 3, 13, 17, 19, and 21, a total loss of the X chromosome, and from the
characterizing element, the partial gain of chromosome 1. Moreover, 5/14 cells showed a partial loss
in that chromosome (1p32.2–1p21.3) and the partial gain of the chromosomal region 2p25.3–2p21; only
1 of these 5 cells also presented a peculiar gain of chromosome 9.
In the chromosomal region 7q32.1–7q36.3, in addition to NRF-1 and BRAF, involved in several
cancers [31], there are another 2 interesting genes, namely EPHB6 (whose levels have been proposed as
prognostic indicators in NB [32]), and EZH2 (which plays an essential role in the control of the central
nervous system by regulating the dopamine D4 receptor [33]).
MCAM and TMPRSS4, localized in the chromosomal region 11q13.3–11q25, play a role in invasion,
metastasis, migration, and adhesion; of considerable interest, there is also Fli-1, which plays an
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important role in erythropoiesis; in particular, the expression of the EWS/Fli-1 fusion gene has been
shown to be critical for cancer induction in the majority of Ewing’s sarcomas [34,35].
The analysis of the altered chromosomal regions found in the SK-N-BE (2)-C cells revealed the
presence of many genes related to the development and progression of the cancer, as shown in Table 2.
However, here, we discuss those of greatest interest for NB. For example, FOXPI is localized in the
chromosomal region 3p26.3–3p14.2.1, a locus often found to be deleted in NB tumors. This locus codes
for a set of transcription factors that largely control normal cellular processes, like proliferation and
differentiation. The deletion of this locus largely explains the tumor development in NB patients [36].
It has been reported that the FOXP1 expression level is consistently lower in Stage 4 patients, which
corresponds to a poor NB prognostic index. On the contrary, the normal expression of FOXP1
significantly marks the overall survival rate. PPARG and TGFBR2 (3p26.3–3p14.2), BRCA2, and KLF5
(13q12.11–13q31.1) are linked to many pathological conditions, including cancer; MLH1 and BAP1,
whose loss of expression is correlated with microsatellite instability in colorectal cancer and breast
cancer, respectively; and finally, NF1 (17p13.3–17q11.2) related to type 1 neurofibromatosis [37,38].
The analysis of 5/14 cells showed a gain region in chromosome 2: we must remember that
SK-N-BE(2)-C is a clonal subline of the SK-N-BE(2) NB cell line. Like the parental cell line, these cells
display MYCN amplification, which correlates with the gain of the chromosomal region 2p25.3–2p21
(where MYCN is located), which is the same alteration we found. The rare forms of familial NB are
also featured by MYCN overexpression [9].
Moreover, in the 2p35 region, within BARD1, several SNPs have been identified and associated
with a more aggressive tumor behavior [39,40]. This region is also characterized by the presence of
2 genes, SOX11 and ALK, which may have a role in nervous system development and maintenance;
in particular, ALK is highly expressed in familial and sporadic NB patients. ALK plays an important
role in brain development and exerts its effects on specific neurons. It belongs to the tyrosine kinase
receptors family with typical transmembrane and extracellular domains. Knocking out ALK gene
mRNA effectively inhibits cells growth. Constitutive activation of ALK is due to translocation [41].
Moreover, the ID2 gene, a key regulator in the phenotypic transition of neuroblastoma tumor cells, is
also present [42].
Only in 1 cell was there found a gain of the chromosomal region 9p24.3–9p23, where PTPRD is
located, which has been reported to act like a tumor suppressor gene in NB, in addition to other genes,
indicated to be related to cancer (i.e., JAK2, RLN2, TYRP1) [43].
Taken together, our results show a high heterogeneity of the CNV status of single cells, although
belonging to an immortalized cell line. In fact, despite having analyzed single cells from immortalized
cell lines, we found a high inter-cellular heterogeneity, confirming that each cell may potentially
accumulate different alterations, which can modulate its behavior, underlining the importance of a
precise diagnostic and therapeutic approach for each single patient.
It is commonly observed that, despite the presence of a given biomarker resulting in being
positive after tumor biopsy, patients can be resistant to a given therapy. Our data, obtained from the
single-cell analysis, could explain this lack of response to targeted agents, according to the well-known
intra-patient heterogeneity. Indeed, rare genomic variations in a single cell could be missed by a bulk
analysis of the sample; instead, the single-cell analysis allows identifying alterations present in the less
represented clones of the primary tumor. Preclinical studies have already shown the importance of
single-cell expression analysis for targeted therapy in breast cancer models [44].
Therefore, the proposed protocol, which aims to evaluate the CNVs on a single cell and then
reconstruct its chromosomal patterns, is in line with some data that suggest that gene expression
profiles could be more informative in terms of functional status with respect to genetic mutations [45].
Based on our findings, we can speculate that cells with chromosomal alterations, involving the principal
genes related to cell proliferation and migration, could mostly contribute to cancer progression. Further
studies will be needed to find cell surface antigens able to classify, isolate, and culture different cell
types in order to evaluate their contribution to cancer development and/or progression.
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Monitoring the evolution of the cellular heterogeneity of a disease from the early stages could help
to identify more aggressive Circulating Tumor Cell (CTC) clones and thus establish a more specific
therapeutic approach [46–48].
In addition to CTCs, the combination of DEPArray and NGS could be applied also for Formalin-Fixed
Paraffin-Embedded (FFPE) tissues as an additional tool for cancer genetic diagnostic purposes [49].
In summary, these data highlight the substantial intra-tumor heterogeneity that occurs at the
single-cell level and support the proposed protocol for the analysis of CNVs and the determination
of chromosomal patterns at the single-cell level, as a diagnostic and therapeutic strategy for
precision medicine.
4. Materials and Methods
The protocol, developed on 2 NB cell lines, SK-N-BE (2)-C and IMR-32, includes: (a) the
identification and separation of each single cell in a single tube; (b) the preliminary Whole Genome
Amplification (WGA) step; (c) the NGS for the detection of the CNVs; and (d) the software for the
analysis of the chromosomal patterns.
4.1. Cell Lines
The 2 NB cell lines, SK-N-BE (2)-C and IMR-32, used in this study were kindly provided by
the cell culture facility of CEINGE-Biotecnologie Avanzate s.c.a.r.l.; the cell lines were cultured at
37 ◦C with 5% CO2 in a humidified atmosphere. NB cell lines were grown in Minimal Essential Eagle
Medium (MEM; Sigma, St. Louis, MO, USA) with 10% heat-inactivated FBS (Sigma, St. Louis, MO,
USA), 1 mmol/L L-glutamine, penicillin (100 U/mL), and streptomycin (100 mg/mL; Thermo Fisher
Scientific, Carlsbad, CA, USA). The cell lines used for all the experimental procedures described herein
were tested as mycoplasma free. Experiments were performed on early passage cells.
4.2. Isolation of Intact Single Cells by DEPArrayTM
The DEPArray™ System is an automated instrument able to identify, sort, and recover individual
rare cells, after a preliminary cell immunofluorescence staining. Once collected from the cell culture
plate, 500,000 cells for each cell line were suspended in the Running Buffer (RB: PBS with BSA 0.5%
and EDTA 2 mM), fixed in 2% PFA at Room Temperature (RT) for 20′, suspended in blocking solution
with 3% BSA at RT for 10′, and processed for the immunofluorescence staining. The cells were firstly
filtered (by a 30-micrometer filter) in the RB and then incubated with 100 µL of primary antibody
(mouse anti-human GD2; BD Biosciences, San Jose, CA, USA) at 4 ◦C for 60′. GD2 has been used
extensively as a target in mAb therapy and has been the primary target of antibody recognition in
NB [50]. The cells were then incubated at 4 ◦C for 60′ with secondary antibody (goat anti-mouse APC;
Abcam, Cambridge, UK), suspended in a permeabilizing solution with 100 µL of triton 0.2% for 5′,
and stained with 100 µL of Hoechst solution for 5′ at RT. After incubation, cells were washed twice
by adding 1 ml of RB and centrifuged at 2000 rpm for 5′. An aliquot of each sample (~1 mL) was
transferred into a clean 1.5-mL tube, filled, washed twice with 1 mL of SB115 buffer (Silicon Biosystems,
Bologna, Italy) at RT, and centrifuged at 1000× g for 5′. Between different steps, when not detailed
above, cells were washed thrice with 1 mL of PBS and centrifuged at 2000 rpm for 5′.
For the sorting process, 5000 cells in 13 mL were loaded with 380 mL of the manipulation buffer
(SB115, Silicon Biosystem, Bologna, Italy) into an A300K cartridge (Silicon Biosystem, Bologna, Italy).
This single-use, microfluidic cartridge contains an array of individually-controllable electrodes, each
with embedded sensors. This circuitry enables the creation of Dielectrophoretic (DEP) cages around
the cells. Individual cells of interest are gently moved to specific locations on the cartridge or into the
holding chamber for their isolation and recovery. The cartridge was then scanned by an automated
fluorescence microscope; this optic system provides a 10× magnification (0.64 micron/pixel) and
a 20× magnification (0.32 micron/pixel) resolution. The CellBrowser software (Silicon Biosystem,
Bologna, Italy) allows cell selection based on multiple parameters from fluorescence and bright field
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images. The protocol chosen was fixed low-density cells, and the chip-scan setting included DAPI,
Brithfield, and APC. Firstly, cells able to move were grouped, and then, based on APC, fluorescent
cells were isolated as GD2 positive. High-quality, image-based selection allows the identification and
isolation of the cells of interest. Taking into account the SB115 starting volume, the DEPArray allows
isolating a maximum of 35 single cells. Each cell was individually collected, washed twice in PBS,
and stored at −20 ◦C until the WGA.
4.3. Whole Genome Amplification
Cell lysis and genome amplification were performed using the SurePlexTM DNA Amplification
System (Illumina, San Diego, CA, USA), following the manufacturer’s instructions. A negative no
template control (2.5 µL of PBS) and a SurePlex-positive control (15 pg of genomic DNA) were used for
each reaction. In brief, each single cell underwent lyses and DNA extraction, SurePlex pre-amplification,
and finally, the SurePlex amplification step. To determine the success of the amplification, 5 µL of each
amplified sample plus 5 µL gel loading buffer (2×) were loaded on a 1.5% agarose 1× TBE gel. WGA
products were quantified using the Qubit dsDNA High Sensitivity Assay kit (Thermo Fisher Scientific,
Carlsbad, CA, USA).
4.4. Next Generation Sequencing
WGA samples were analyzed by NGS using the VeriSeq PGS Kit (Illumina, San Diego, CA,
USA), a system specifically designed for single-cell analysis and able to provide a comprehensive
and accurate screening of all 24 human chromosomes in approximately 12 h. Tagmentation, sample
barcoding, and libraries’ preparation were all performed using the manufacturer’s protocol. Then,
the products were purified by using a size selection and normalized to equalize the quantity of each
sample. The final products were pooled, denatured, and sequenced using the MiSeq Reagent Kit v3,
PGS (Illumina, San Diego, CA, USA) on a MiSeq System.
4.5. Data Analysis
NGS results were analyzed using the BlueFuse Multi Software V4.4 (Illumina, San Diego, CA, USA),
a complete solution for analyzing and reporting the VeriSeq results by enabling a full understanding of
the status of each chromosome and the results’ confirmation. Sophisticated algorithms calculate and
call the status for each chromosome, as either normal or abnormal, and include an estimate of the
confidence in the call based on the assay noise or on any underlying ambiguity. In particular, for
sequencing data, the number of sequences is proportional to the copy number, so a greater or lower
number of reads will correspond to the gain or loss of chromosomal regions.
Once CNVs were detected in each analyzed single cell, we verified for each altered chromosomal
region which genes were comprised in them. The genes were referenced from the Atlas Genetics
Oncology.org (http://atlasgeneticsoncology.org, accessed on September 2018), an open access website
that contains all the information about the genes that have been related to cancer. Genes were selected
based on their position in chromosomes that correlated with our NGS findings, as well as on their
direct correlation with tumor progression and tumor development in various cancers, apart from NB.
5. Conclusions
Our data show that the combined use of DEPArrayTM technology with high-coverage NGS
provides a good method to identify and explore CNVs, from which it is possible to screen the
chromosomal patterns in cancer cells, and it is a well-established approach to examine tumor genetic
heterogeneity. Furthermore, the chromosomal pattern evaluation of the collected single cells may be
useful to highlight the driving mutations responsible for disease progression and therapy response.
These preliminary data encourage the application of this protocol also in other types of cancers and
support the idea that the identification of chromosomal patterns, rather than individual biomarkers,
could demonstrate the value of liquid biopsy as a diagnostic and prognostic tool.
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IMR-32 Neuroblastoma cell line
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CNVs Copy Number Variants
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